AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: Model veterinarian gender
Number of subjects: 449
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant education level
Number of subjects: 449
Study 36336249 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose digital health intervention (1 session)
Number of subjects: 74
Study 36336249 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose digital health intervention (12 sessions)
Number of subjects: 74
Study 36336249 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 74
Study 32968933 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted colonoscopy
Number of subjects: 150
Study 32968933 — intervention group
Group type: COMPARATOR
Intervention: Traditional colonoscopy
Number of subjects: 150
Study 32756067 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified cognitive training (CT) intervention for 12 weeks
Number of subjects: 41
Study 32756067 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 41
Study 35449109 — intervention group
Group type: EXPERIMENTAL
Intervention: TCY‐MIT combined with CRTs (30 min per day, 6 days per week, for 3 weeks)
Number of subjects: 78
Study 35449109 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation therapies (CRTs) (40 min per day, 6 days per week, for 3 weeks)
Number of subjects: 78
Study 35449109 — intervention group
Group type: EXPERIMENTAL
Intervention: TCY‐MIT combined with CRTs
Number of subjects: 78
Study 32935270 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 247
Study 32935270 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 247
Study 32047010 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid (PDA)
Number of subjects: 186
Study 32047010 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study 35399576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chest tube clamping
Number of subjects: 180
Study 35399576 — intervention group
Group type: COMPARATOR
Intervention: Continuous gravity drainage
Number of subjects: 180
Study 34021173 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive embodied avatar VR
Number of subjects: 24
Study 34021173 — intervention group
Group type: COMPARATOR
Intervention: Passive VR (no avatar and no interactivity)
Number of subjects: 24
Study 35925914 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra plus optimized standard of care (oSOC)
Number of subjects: 71
Study 35925914 — intervention group
Group type: COMPARATOR
Intervention: Optimized standard of care (oSOC) alone
Number of subjects: 71
Study 34724631 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea prevalence
Number of subjects: 576
Study 33017120 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL)
Number of subjects: 42
Study 33017120 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo treatment)
Number of subjects: 42
Study 32365251 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 1102
Study 32365251 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab 45/90 mg
Number of subjects: 1102
Study 32130991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral double incisions group
Number of subjects: 41
Study 32130991 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial and lateral incisions group
Number of subjects: 41
Study 32130991 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study 35850110 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise intervention (moderate- and vigorous-intensity levels)
Number of subjects: 36
Study 35850110 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise intervention (moderate- and vigorous-intensity levels)
Number of subjects: 36
Study 35850110 — intervention group
Group type: COMPARATOR
Intervention: Non-active control group
Number of subjects: 36
Study 33473026 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination technique (acute normovolemic hemodilution, retrograde autologous priming, integrated arterial filter oxygenator)
Number of subjects: 300
Study 33473026 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass technique
Number of subjects: 300
Study 32465897 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 81
Study 34801263 — intervention group
Group type: EXPERIMENTAL
Intervention: Occult lymph node metastasis (LNM) in patients with clinical T1 through T2 N0 esophageal cancer
Number of subjects: 675
Study 34801263 — intervention group
Group type: COMPARATOR
Intervention: Patients with clinical T1 through T2 N+ cancer who underwent neoadjuvant therapy plus surgery
Number of subjects: 675
Study 34801263 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for occult LNM based on the risk model
Number of subjects: 675
Study 34801263 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring system based on the model
Number of subjects: 675
Study 34736011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 397
Study 34736011 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 397
Study 35532966 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, self-administered Stop and Go Switching Task
Number of subjects: 7410
Study 35532966 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, self-administered Figure Identification test
Number of subjects: 7410
Study 32846041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry extract (BE) supplementation for 8 weeks
Number of subjects: 0
Study 35613783 — intervention group
Group type: EXPERIMENTAL
Intervention: PHOENIX intervention
Number of subjects: 375
Study 35613783 — intervention group
Group type: COMPARATOR
Intervention: Active control (FRAX questionnaire only)
Number of subjects: 375
Study 35613783 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 375
Study 35613783 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 375
Study 33608734 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to insomnia symptoms
Number of subjects: 218379
Study 33608734 — intervention group
Group type: COMPARATOR
Intervention: Manifested pain
Number of subjects: 218379
Study 32054473 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted lung denervation (TLD) combined with optimal medical therapy
Number of subjects: 400
Study 32054473 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 400
Study 34481017 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus short-term ADT (flutamide with goserelin or leuprolide for 4 months)
Number of subjects: 2028
Study 34481017 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 2028
Study 34481017 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus short-term ADT
Number of subjects: 2028
Study 34286370 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization (PAE)
Number of subjects: 0
Study 34286370 — intervention group
Group type: COMPARATOR
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 0
Study 35894970 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic format of the IPAB
Number of subjects: 66
Study 35894970 — intervention group
Group type: COMPARATOR
Intervention: Pen-and-paper format of the IPAB
Number of subjects: 66
Study 33757723 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (20 U/0.5 mL administered intranasally for 2 days prior to surgery)
Number of subjects: 90
Study 33757723 — intervention group
Group type: COMPARATOR
Intervention: Control (0.5 mL saline administered intranasally for 2 days prior to surgery)
Number of subjects: 90
Study 33757723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 34427156 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 53
Study 34427156 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance and resistance training
Number of subjects: 53
Study 32494942 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=19) received text messages on job openings, educational sessions, mentoring, a start-up grant, and business and HIV prevention text messages.
Number of subjects: 38
Study 32494942 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n=19) received text messages on job openings only.
Number of subjects: 38
Study 36153560 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application
Number of subjects: 210
Study 36153560 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital book
Number of subjects: 210
Study 36153560 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study 32706738 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH text message intervention (daily texts for first 6 months, option to reduce frequency for last 6 months)
Number of subjects: 248
Study 32706738 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH text message intervention with monthly phone coaching for first 6 months
Number of subjects: 248
Study 32706738 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who continued daily text messages for the last 6 months
Number of subjects: 248
Study 32706738 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who chose fewer texts
Number of subjects: 248
Study 32706738 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement analysis
Number of subjects: 248
Study 36451389 — intervention group
Group type: EXPERIMENTAL
Intervention: Yaobitong capsule
Number of subjects: 258
Study 36451389 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib capsule
Number of subjects: 258
Study 34708639 — intervention group
Group type: EXPERIMENTAL
Intervention: Songlingxuemaikang (SLXMK) 500 mg per capsule, 4500 mg/d, n = 60
Number of subjects: 90
Study 34708639 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium 50 mg per tablet, 50 mg/d, n = 30
Number of subjects: 90
Study 32041914 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) supplementation at 600 mg every 8 hours for 3 days
Number of subjects: 32
Study 32041914 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 32
Study 34360312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise (n = 8)
Number of subjects: 29
Study 34360312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-only (n = 6)
Number of subjects: 29
Study 34360312 — intervention group
Group type: COMPARATOR
Intervention: Control/No Intervention (n = 15)
Number of subjects: 29
Study 35901337 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy with concurrent temozolomide and adjuvant temozolomide
Number of subjects: 71
Study 35901337 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy alone
Number of subjects: 71
Study 34429149 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol (1 g paracetamol + 3.91 g mannitol per 100 mL), n=12
Number of subjects: 24
Study 34429149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% Saline 100 mL), n=12
Number of subjects: 24
Study 32018030 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 32018030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32018030 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus-16 inoculation
Number of subjects: 0
Study 35292490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests after each visit with a conversational artificial intelligence bot.
Number of subjects: 0
Study 35292490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability questionnaires after each visit.
Number of subjects: 0
Study 35292490 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomisation to receive cognitive test results either after each visit or only after completing the study.
Number of subjects: 0
Study 33539734 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine plus alcohol
Number of subjects: 1000
Study 33539734 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovation group (closed integrated catheters, positive displacement needleless‐connectors, disinfecting caps, and single‐use prefilled flush syringes)
Number of subjects: 1000
Study 33539734 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine plus alcohol
Number of subjects: 1000
Study 33143764 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 0 days, then refeeding for 14 days
Number of subjects: 120
Study 33143764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 3 days, then refeeding for 14 days
Number of subjects: 120
Study 33143764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 7 days, then refeeding for 14 days
Number of subjects: 120
Study 33143764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 14 days, then refeeding for 14 days
Number of subjects: 120
Study 33143764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 7 days
Number of subjects: 120
Study 33143764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 14 days
Number of subjects: 120
Study 33143764 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding after fasting
Number of subjects: 120
Study 33469958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 4
Study 36079902 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐ supplementation
Number of subjects: 14
Study 33874993 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml levobupivacaine 0.25%
Number of subjects: 48
Study 33874993 — intervention group
Group type: COMPARATOR
Intervention: 20 ml levobupivacaine 0.25%
Number of subjects: 48
Study 32446311 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus Liu‐zi‐jue (a mind‐body exercise)
Number of subjects: 0
Study 32446311 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 34436552 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach Plus Message
Number of subjects: 161
Study 34436552 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach Plus Phone
Number of subjects: 161
Study 34436552 — intervention group
Group type: COMPARATOR
Intervention: Reach Plus
Number of subjects: 161
Study 36274326 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR) for 9 weeks
Number of subjects: 773
Study 36274326 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) for 9 weeks
Number of subjects: 773
Study 36274326 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR)
Number of subjects: 773
Study 32006073 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic 2-incision operation with partial fasciotomy and heel spur removal followed by a controlled strength training program
Number of subjects: 30
Study 32006073 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment with corticosteroid injections and a controlled strength training program
Number of subjects: 30
Study 36478142 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (20, 80 or 240 mg) as monotherapy
Number of subjects: 103
Study 36478142 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (240 mg) in combination with metformin
Number of subjects: 103
Study 36478142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 36478142 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 treatment
Number of subjects: 103
Study 34081076 — intervention group
Group type: EXPERIMENTAL
Intervention: apalutamide+ADT
Number of subjects: 233
Study 34081076 — intervention group
Group type: COMPARATOR
Intervention: placebo+ADT
Number of subjects: 233
Study 32841523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) aimed at weight loss
Number of subjects: 4859
Study 32841523 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4859
Study 32841523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4859
Study 32773602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA), median maximal tolerated dose 1663 mg/day
Number of subjects: 27
Study 32773602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 32773602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 27
Study 33198767 — intervention group
Group type: EXPERIMENTAL
Intervention: ENhanced Recovery In CHildren Undergoing Surgery (ENRICH‐US) intervention
Number of subjects: 18
Study 33198767 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCED RECOVERY PROTOCOL
Number of subjects: 18
Study 34057707 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (all doses combined)
Number of subjects: 297
Study 34057707 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (open-label extension)
Number of subjects: 297
Study 34057707 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (double-blind treatment)
Number of subjects: 297
Study 34057707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 35534443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus complex capsules (probiotics group)
Number of subjects: 69
Study 35534443 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated aspirin only (control group)
Number of subjects: 69
Study 32875383 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 8 mg plus ETO 300 mg (DEX + ETO)
Number of subjects: 60
Study 32875383 — intervention group
Group type: COMPARATOR
Intervention: DEX 8 mg (DEX)
Number of subjects: 60
Study 32875383 — intervention group
Group type: COMPARATOR
Intervention: ETO 300 mg (ETO)
Number of subjects: 60
Study 32875383 — intervention group
Group type: COMPARATOR
Intervention: Control (Paracetamol 750 mg as rescue analgesics)
Number of subjects: 60
Study 32875383 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 35409460 — intervention group
Group type: EXPERIMENTAL
Intervention: Masticatory Muscle Training (MaMuT) - part 1: three physiotherapeutic treatments and daily home exercises; part 2: daily home exercises only
Number of subjects: 3
Study 35409460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3
Study 32613281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 656
Study 32613281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study 34310044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-like diet (Med-diet)
Number of subjects: 87
Study 34310044 — intervention group
Group type: COMPARATOR
Intervention: Western-like diet (West-diet)
Number of subjects: 87
Study 33045886 — intervention group
Group type: EXPERIMENTAL
Intervention: EtCO2: 26 − 35 mmHg (Group A)
Number of subjects: 60
Study 33045886 — intervention group
Group type: COMPARATOR
Intervention: EtCO2: 36 − 45 mmHg (Group B)
Number of subjects: 60
Study 35851507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Vitamin B6 supplementation
Number of subjects: 478
Study 35851507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Vitamin B12 supplementation
Number of subjects: 478
Study 35851507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 33819750 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with standard of care
Number of subjects: 432
Study 33819750 — intervention group
Group type: COMPARATOR
Intervention: Standard of care without HIPEC
Number of subjects: 432
Study 35797643 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Dermatome Laparoscopic Appendectomy (SDLA)
Number of subjects: 0
Study 35797643 — intervention group
Group type: COMPARATOR
Intervention: Standard Laparoscopic Appendectomy (SLA)
Number of subjects: 0
Study 33813962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy + low energy percutaneous RF thermocoagulation
Number of subjects: 111
Study 33813962 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 111
Study 33813962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 111
Study 33813962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy + RF thermocoagulation
Number of subjects: 111
Study 32899045 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishe pill
Number of subjects: 330
Study 33675351 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose FA (4.0 mg daily)
Number of subjects: 50
Study 33675351 — intervention group
Group type: COMPARATOR
Intervention: Low-dose FA (≤1.1 mg daily)
Number of subjects: 50
Study 36401223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BW (≤ 2500 g)
Number of subjects: 4005
Study 36401223 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BW (2500 g < BW ≤ 3500 g)
Number of subjects: 4005
Study 36401223 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BW (> 3500 g)
Number of subjects: 4005
Study 32040379 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent cell-based influenza vaccine (QIVc)
Number of subjects: 2500000
Study 32741231 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm sling
Number of subjects: 57
Study 32741231 — intervention group
Group type: COMPARATOR
Intervention: No arm sling
Number of subjects: 57
Study 32343211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based ultrasound (US) for assessing bone age
Number of subjects: 128
Study 36329602 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of almond paste and 4 g of inulin
Number of subjects: 15
Study 36329602 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ingestion of almond paste with bread
Number of subjects: 15
Study 32430429 — intervention group
Group type: EXPERIMENTAL
Intervention: Total antibody (Ab)
Number of subjects: 80
Study 32430429 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM
Number of subjects: 80
Study 32430429 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG
Number of subjects: 80